Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HB-0034 by Huabo Biopharm (Shanghai) for Pyoderma Gangrenosum: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Pyoderma Gangrenosum. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Hidradenitis Suppurativa: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Squamous Cell Carcinoma: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Squamous Cell Carcinoma. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Systemic Lupus Erythematosus: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Systemic Lupus Erythematosus. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Ulcerative Colitis: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Ulcerative Colitis. According to GlobalData,...
HB-0045 by Huabo Biopharm (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
HB-0036 by Huabo Biopharm (Shanghai) for Melanoma: Likelihood of Approval
HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Melanoma. According to GlobalData, Phase...
HB-0025 by Huabo Biopharm (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Non-Small Cell Lung Cancer. According...
HB-0025 by Huabo Biopharm (Shanghai) for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Squamous Non-Small Cell Lung Cancer....
HB-0025 by Huabo Biopharm (Shanghai) for Endometrial Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Endometrial Cancer. According to GlobalData,...
HB-0025 by Huabo Biopharm (Shanghai) for Renal Cell Carcinoma: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Renal Cell Carcinoma. According to...
HB-0025 by Huabo Biopharm (Shanghai) for Hepatocellular Carcinoma: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
HB-002.1T by Huabo Biopharm (Shanghai) for Extrahepatic Bile Duct Cancer: Likelihood of Approval
HB-002.1T is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Extrahepatic Bile Duct Cancer. According...